Therapeutic Asset Ratings

153 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
FILGRASTIM Hereditary Anemias	Paul Szabolcs	P2	CCC (53)
FILGRASTIM Inflammatory Conditions	Paul Szabolcs	P2	CCC (53)
FILGRASTIM Juvenile Rheumatoid Arthritis	Paul Szabolcs	P2	CCC (53)
FILGRASTIM Systemic Juvenile Idiopathic Arthritis (sJIA)	Paul Szabolcs	P2	CCC (53)
Fludarabine CD40 Deficiency	Paul Szabolcs	P2	CCC (53)
Fludarabine CD40 Ligand Deficiency	Paul Szabolcs	P2	CCC (53)
Fludarabine Chronic Granulomatous Disease	Paul Szabolcs	P2	CCC (53)
Fludarabine Common Variable Immunodeficiency	Paul Szabolcs	P2	CCC (53)
Fludarabine Congenital Bone Marrow Failure Syndromes	Paul Szabolcs	P2	CCC (53)
Fludarabine DiGeorge Syndrome	Paul Szabolcs	P2	CCC (53)
Fludarabine Hereditary Anemias	Paul Szabolcs	P2	CCC (53)
Fludarabine Hypomorphic RAG1 Deficiency	Paul Szabolcs	P2	CCC (53)
Fludarabine Hypomorphic RAG2 Deficiency	Paul Szabolcs	P2	CCC (53)
Fludarabine Immune Dysregulation	Paul Szabolcs	P2	CCC (53)
Fludarabine Inflammatory Conditions	Paul Szabolcs	P2	CCC (53)
Fludarabine IPEX	Paul Szabolcs	P2	CCC (53)
Fludarabine Juvenile Rheumatoid Arthritis (JRA)	Paul Szabolcs	P2	CCC (53)
Fludarabine Mendelian Susceptibility to Mycobacterial Disease	Paul Szabolcs	P2	CCC (53)
Fludarabine Omenn Syndrome	Paul Szabolcs	P2	CCC (53)
Fludarabine STAT 1 Gain of Function	Paul Szabolcs	P2	CCC (53)
Fludarabine STAT 3 Gain of Function	Paul Szabolcs	P2	CCC (53)
Fludarabine Systemic Juvenile Idiopathic Arthritis (sJIA)	Paul Szabolcs	P2	CCC (53)
Hydroxyurea Congenital Bone Marrow Failure Syndromes	Paul Szabolcs	P2	CCC (53)
Hydroxyurea Hereditary Anemias	Paul Szabolcs	P2	CCC (53)
Hydroxyurea Inflammatory Conditions	Paul Szabolcs	P2	CCC (53)

Showing 51 to 75 of 153 assets

PreviousPage 3 of 7Next